Rising costs, decreasing quality of care, diminishing productivity, and increasing complexity have all contributed to the present state of the healthcare industry. The interactions between payers (e.g., insurance companies and health plans) and providers (e.g., hospitals and laboratories) are growing and are becoming more complicated. The constant upsurge in and enhanced complexity of diagnostic and treatment information has made the clinical decision-making process more difficult. Medical transaction charges are greater than ever. Population-specific financial requirements are increasing the economic burden on the entire system. Medical insurance and identity theft frauds are on the rise. The current lack of comparative cost analytics hampers systematic efficiency. Redundant and unnecessary interventions add to medical expenditures that add no value. Contemporary payment models are antithetic to outcome-driven medicine. The rate of medical errors and mistakes is high. Slow inefficient processes and the lack of best practice support for care delivery do not create productive settings. Information technology has an important role to play in approaching these problems. This paper describes IBM Research's approach to helping address these issues, i.e., the evidence-based healthcare platform.
Introduction
Cost, quality, and productivity are the dominant driving forces behind the transformation of the healthcare domain.
High charges, disorganized and inefficient delivery systems, high medical and medication error rates, poor communication and care coordination, the lack of information support for effective decision making, and counterproductive payment incentives characterize the present state of healthcare systems [1, 2] . In order to improve this situation, information technology (IT) has to be used to enable healthcare transformation, which involves replacing poorly coordinated acute-focused episodic care with coordinated management for preventive, acute, chronic, long-term, and end-of-life care.
Starting a few decades ago, IBM Research (in China, Israel, Taiwan, and the United States) slowly began utilizing technology to collect, collate, and provide (hidden or buried) information or evidence to improve decision making and to provide insight from the application of advanced analytics on clinical, claims, and other health data. These efforts and technologies have culminated in IBM Research's evidence ecosystem (EE) vision and platform illustrated in Figure 1 .
At the highest conceptual level, Figure 1 presents the team's framework for business process modeling and transformation that enables the delivery of consumable evidence at the point of care and the introduction and integration of novel incentive and outcome-based payment models. There will be business models that generate revenue for evidence providers and rewards for improved outcomes from evidence use. Providers get paid by payers for improved outcomes and usage of best practices. Payers consume evidence on best practices and appropriate treatments in order to pay providers based on appropriate use.
Evidence generation requires aggregation of patient records, claims data, wellness data, and results from medical studies, such as randomized controlled trials (RCTs) and quasi-experimental, community observation studies. The comparative effectiveness engine in Figure 1 compares outcomes among patients with similar disease progressions (i.e., cohorts). The evidence registry stores curated evidence, and the service provision mechanism delivers evidence at the point of care.
The process of delivering evidence for end-user consumption requires clinical decision intelligence enhancements that allow the analysis of current interaction and process, the attachment of supporting provenance information (i.e., evidence source data), and the definition and utilization of mechanisms for presenting the evidence in a consumable way that is appropriate to the role of the clinical professional. The monitoring of evidence use helps in the evaluation of the meaningful use of evidence for improving outcomes and lowering costs.
The evidence ecosystem (see Figure 1 ) builds upon work in medical informatics [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , collaborative care [21] [22] [23] [24] [25] [26] [27] , data mining [28] [29] [30] [31] [32] [33] , modeling [34] [35] [36] [37] [38] [39] [40] , software engineering [41] [42] [43] [44] [45] [46] [47] , usability and user interface design [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] , and decision theory [58] [59] [60] [61] [62] [63] [64] [65] [66] . Of these foundational topics, the areas that seek to address a similar space as the evidence ecosystem are patient-centered medical home (PCMH) [3] and evidence-based medicine [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
PCMH is defined as an approach to providing comprehensive primary care that facilitates partnerships between individual patients and their personal providers and, when appropriate, the patient's family. IBM Research's evidence ecosystem platform is a technical means for supporting the PCMH vision. An evidence ecosystem is a technology-based solution that provides powerful analytic tools to process data and to create actionable information.
Evidence-based medicine means applying the best available evidence gained from the scientific method to clinical decision making. Evidence-based medicine attempts to assess the strength of evidence of the risks and benefits of treatments (including lack of treatment) and diagnostic tests. Evidence quality ranges from meta-analyses to systematic reviews of double-blind placebo-controlled RCTs to conventional wisdom. The scientific concerns related to RCTs stem from their external validity and their generalizability. Although RCTs are valuable and a critical source of knowledge and internal validity, both of the aforementioned concerns often limit the scope of use of the generated evidence output from RCTs at the point of care. By leveraging the advanced information acquisition and integration of IBM Research's evidence ecosystem, the team increases the relevant evidence available to the practitioner at the point of care.
In the remainder of this paper, we present the details of the evidence ecosystem platform, describe sample results of the platform's deployment, highlight future work, and conclude.
Platform
As aforementioned (see Figure 1) , the evidence ecosystem platform has three key pillars, namely, evidence generation (EG), evidence use (EU), and evidence-based incentive payment models (IPMs). EG is responsible for extracting useful evidence from existing data repositories, sanitizing it, transforming it into a form that is amenable to integration (with other pieces of evidence), and processing it for consumption by higher-level services. EU is responsible for the manipulation of EG artifacts into a state and visualization that is appropriate for the end user. IPM is responsible for the evidence-based analysis and update of the financial models that engender the best possible care outcomes. In the following sections, we present each component of the platform in greater detail.
Evidence generation
The EG platform (see Figure 2) consolidates heterogeneous clinical data and provides state-of-the-art analytic services that support evidence-based practice, population analytics, best practice guideline support, decision support, and translational medicine. A key difficulty in implementing an EG system stems from working with data that was collected for patient care, but not for research or analysis. Such data is scattered throughout a healthcare organization and spans multiple modalities (or data types), ranging from structured database records to raw text on paper to magnetic resonance images on modern picture archiving and communication systems machines.
Additionally, EG systems must preserve the provenance and track the uncertainty of the data they curate. They need to facilitate proper role-based access to protected health information (PHI) and to support the continuing evolution of data types as new medical testing technologies emerge. The main challenge faced by the team when building the EG system was in creating technology and tooling that meet these requirements and that can reduce the time it takes to transform data into usable evidence in the clinical setting. This task is further complicated by the fact that clinical systems often lacked well-defined application programming interfaces (APIs), that archives had differing uptimes, and that data may be corrupted after years on legacy content management systems. Furthermore, access to data is often gated by the systems' highly distributed nature, the lack of a coherent Bsingle sign-on[ within these environments, and the requirement that access does not interfere with the primary use (e.g., clinical patient care) of these systems. These hurdles are further augmented with the facts that data sets are often quite large, e.g., hours of video and audio transcripts and that, in many cases, the time and processing limits (particularly in emergent care situations) require Bbest effort[ optimization of data acquisition rather than a complete draw or ingest. Fortunately, the team was able to leverage and customize its prior work on data acquisition technologies [41] [42] [43] [44] [45] [46] .
Once data from different systems has been acquired, it needs further transformation before it can be used for analytics. The different vocabularies and coding systems used by different sources must be harmonized so that data is available for analysis in a standard coherent form. Data from multiple sources is combined and reorganized into logical groupings that reflect how the data is to be used, rather than which particular system or device it came from. Additional analytic routines may be run to extract additional information from the source data. For example, entity extractors can tag clinical terms in textual data, and feature extractors can identify structures in images. Since such analyses are often very specific to a particular form of data and new analytics are constantly being devised, the system must allow new analytics to be easily added via a pluggable standardized interface.
Although most analysis routines will consume specific data artifacts and produce new ones, a central point is needed to organize and summarize all of the information about a particular patient into a consistent and coherent longitudinal record. Our approach is to leverage the HL7 Clinical Document Architecture (CDA) standard to provide the organizational structure needed for this patient summary as well as to maintain links to the underlying artifacts used to create it and to preserve the provenance chains for the artifacts themselves. This gives investigators the ability to determine the ultimate source of the information they are utilizing. There are numerous challenges in constructing such a summary, including the need to resolve conflicting information from different sources or to represent uncertainty when conflicts cannot be resolved. The summary provides not just the patient's current state but a snapshot of the patient's state at any point in time.
It should be noted that an increase in the use of standards-compliant electronic medical records will make data acquisition for secondary use (and thus evidence generation) easier over time. However, despite evolving standards and coding systems, the need to integrate historical data from legacy systems persists, and the importance of not interfering with the primary use of systems suggests that evidence generation will remain a difficult task for the foreseeable future.
After solving the myriad issues involved with evidence generation, a solid corpus of data exists in the clinical content management database (see Figure 2 ). At this point, specialized advanced analytics, based on the intended usage, are executed over the data set to create actionable information that will be presented.
Evidence use EU has two phases: 1) advanced analytics and 2) presentation. EU advanced analytics are highly specialized Figure 2 Evidence generation platform.
purpose-driven tasks that transform the data received from the EG platform into the consumable units required by the EU presentation component. As such, the artifacts in the leftmost side of the framework in Figure 2 represent end products of this advanced analytics process. To further elucidate the nature of EU advanced analytics, point examples are highlighted in upcoming sections.
The EU presentation phase entails the processes, procedures, and technologies required to ensure that the right information gets to the right person, at the right moment in time, at the right point in the clinician's workflow, and in the right form. This phase is complicated by the fact that EU is governed by constraints on time, collaboration, transparency, and the nature of intended use.
TimeVThe current modus operandi is that clinicians quickly work in outpatient facilities to see as many patients as possible. Generally, hospital staff members are even more challenged by urgent treatment decisions that must be quickly and accurately made. Thus, user interfaces must be designed to surface summarized patient information and evidence that is most relevant to the current clinical task. The optimization of the EG platform to produce the most current and Bbest effort[ ingests from available systems helps us to meet this constraint. The EU advanced analytics are precisely developed to ensure that dashboarding techniques adapt to the changing condition of a patient, which may cause different data to become relevant over time. CollaborationVThe health of a particular patient is managed by a large team of professionals (e.g., nurses, physicians, and social workers) who must collaboratively work to obtain the best possible outcome for a patient [67] . These professionals typically work asynchronously, seeing patients at different times and often in different facilities. Effective sharing of information across teams is essential, and the presentation layer must have asynchronous collaboration as a fundamental requirement. The design and operation of the platform (in Figure 2 ) helps ensure that clinicians can collaborate not only over a patient's personal health record but also around the relevant medical evidence used to justify various treatment decisions. Evidence transparencyVIt is critical that any displayed evidence provides clear information about the reliability and provenance of the information. Reliability data is garnered from the observed downtimes and ingest rates of the data sources observed by the EG platform, whereas provenance data is acquired from the clinical content management database. Statistical confidence or other reliability data ensures that users of the data understand the weight with which the evidence should influence a decision. Nature of intended useVIdeally, the evidence displayed to a clinician is exactly what is needed and is highly accurate.
In practice, however, expert users such as physicians and nurses will often need to look at evidence from different perspectives before making a decision. This implies that the presentation layer must be able to quickly and smoothly provide different views of the data. Additionally, visualization recommendation techniques [68] may be leveraged to further lighten the cognitive load on healthcare professionals.
As with advanced analytics, the presentation phase is highly dependent on the application being developed, the deployment environment, and the way the practitioners work. Fortunately, active monitoring of how evidence is used is less specialized, and the examination of the patterns of use enables us to determine the interventions that yield desired outcomes, affording us the opportunity to modify the IPMs to better align financial reward with ever-increasing quality of care.
Evidence-based incentive payment models Health policymakers in the United States are encouraging provider organizations to deliver healthcare services that, among other things, include payments that reward specified improvements in quality and costs [69] . The premise behind this effort is that health recommendations are more likely to be implemented when the clinical evidence supports them and sufficient financial incentives exist for providers to follow them. In line with this, the EE platform (Figure 1 ) supports practice environments where providers combine their knowledge of both the clinical evidence and the financial incentives to set treatment strategies for their patients (see Figure 1 ). Currently, with few exceptions [70] , practical guidelines for implementing the necessary provider payment models are unavailable, as are tools for forecasting their impact over time. Our work on evidence-based IPMs is still in its early stages, the following two sections outline our initial thoughts on model design and software tooling for supporting payment-related decisions.
Model design
To model the impact of a given payment incentive on health outcomes, we consider four key aspects for analysis, which include contract design, decision making, resource allocation, and patient-provider attribution. In this context, contract design involves determining the essential components of a financial agreement between a payer and a provider that will encourage provider behavior that is consistent with evidence-based practices. Important dimensions of analysis in contract design include the setting of performance measures, payment structures, and payment rates. More generally, contracts may also be written between payer and patient and between provider organizations and individual providers. Decision making involves the determination of the actions of a decision maker (e.g., payer, provider, and patient) that will optimize the decision maker's preferences. It provides the logical basis for the payer, provider, and patient responses to a given contract. Resource allocation models are used to determine how resources are to be utilized. They can be an important aspect for analysis when decisions are constrained by a limitation in critical resources (e.g., time, staff, beds, rooms, equipment, and other medical supplies). Provider-patient attribution refers to the problem of assigning accountability for the cost of care and health outcomes of particular patients to particular providers. This assignment is reflected in the contract design since it will affect payments. All four aspects are closely related and contribute to the quality of the analysis of payment incentives.
The use of agency theory for contract design is well known in economics and business [71, 72] . The general relevance of agency theory in the healthcare industry is well documented [59] [60] [61] , particularly in regards to physician reimbursement [73] [74] [75] [76] . However, the majority of these efforts make limited, if any, use of empirical data to validate modeling assumptions. A notable exception is the work done by Lee and Zenios [77] who used a data-driven evidence-based approach for designing reimbursement contracts in the context of care delivery for Medicare patients with end-stage kidney disease. Our goal is to provide another validation point for evidence use in incentive and payment model reform.
With respect to decision making, decision theory, which includes expected utility theory [78] and its many generalizations [79] and alternatives [80] , allows us to develop mathematical models of the beliefs and preferences of physicians, patients, and payers. Examples of the use of decision theory in medical decision making are provided in [62] [63] [64] . Additionally, these preference models may be combined with normative models for determining behavior (e.g., choice of treatment). Methods for formulating and solving normative decision models are drawn from machine learning, control theory, and operations research [81] [82] [83] [84] . Dynamic modeling approaches such as system dynamics [85] and stochastic dynamic programming [86] may be used to study the time-dependent effects of alternative payment models. We adapt models like these by parameterizing them based on evidence provided by the EG platform.
The attribution of patients to providers, who are accountable for their care, can be done prior to the delivery of care (i.e., prospectively) or after the delivery of care (i.e., retrospectively). If prospectively done, the problem can be formulated using mathematical optimization methods (e.g., a two-stage stochastic decision model [87] , where in the first stage, the decision maker selects the attribution pattern, and in the second stage, the decision maker selects the treatment choices). The attribution of accountability retrospectively is far from trivial. However, analyses of claims data and referral patterns could assist in assigning responsibility across multiple physicians.
Our current efforts are centered on the first two aspects of analysis for evidence-based payment modeling (i.e., contract design and decision making). The ability to use historical evidence to support the analysis of radically new payment paradigms is, however, a source of concern.
Software tooling
As a standard healthcare setting is complex, tooling that enables the construction and analysis of multiple factors in an interconnected network of simulation models is required. Discrete-event simulation [65] and agent-based simulation [66, 88, 89] are just a few examples of the types of simulation models used in such a network. A significant technical challenge is that of the interoperability of models, which may be implemented using different programming languages and paradigms. This is an important challenge since the management of many chronic diseases such as obesity is multifaceted, involving cultural, social, political, industrial, and infrastructural issues. Models representing different aspects of the community may independently exist and would need to be integrated in order to perform a more complete analysis of the disease. Toward this goal, the IBM Smarter Planet* Platform for Analysis and Simulation of Health (SPLASH) framework [90] is being built.
As the EG and EU components of IBM Research's evidence ecosystem are more mature than the IPMs component, we outline the EG and EU deployment results first.
Platform deployment results
From the prior discussions, it should be apparent that IBM Research's evidence ecosystem (see Figure 1 ) directly and explicitly addresses the problems that have precipitated the need for healthcare to be transformed. It should also be clear that the platform may be (and needs to be) instantiated into point solutions to demonstrate its value via the EU component. It is in its deployment that one recognizes the true potential for the evidence ecosystem to create and deliver new and intriguing health systems.
Here, we present mature instantiations of the evidence ecosystem, where the EG and EU components, along with specialized task-specific advanced analytics, are used to solve difficult problems that were previously thought to be too intractable to be addressed, namely, 1) providing timely and detailed snapshots of patients for cardiologists, 2) enabling the delivery of care in a collaborative environment, 3) reducing the rates of essential hypertension, 4) detecting adverse drug reactions, 5) preventing the spread of epidemics, and 6) helping to determine the best treatment strategies for human immunodeficiency virus (HIV).
Cardiac decision support
The team at the IBM Almaden Research Center [91] [92] [93] [94] leveraged the evidence ecosystem to acquire, analyze, and correlate information from patients' electronic medical records and from their echocardiogram (i.e., echo) data, along with associated reports, to provide cardiologists with up-to-date and accurate information on the cases in their current roster. The specialized analytics in the EU component examined the echo data to calculate measurements (i.e., ejection fraction and ventricular volume) that were used to estimate heart performance and to find similar patients from a prediagnosed patient population based on raw clinical data of new undiagnosed patients. Collaborative filtering was used to derive the distribution of dominant diagnosis, treatment, and outcomes from the similar patient population. This solution enabled cardiologists to speed up the time taken to get near-complete information on a patient from weeks to hours, which had the positive effect of reducing time wasted and unnecessary costs expended due to missing (or still being processed) data.
Collaborative care
The IBM Thomas J. Watson Research Center team [95] [96] [97] used the ecosystem to leverage the collective wisdom of all the patients in an institution to drive more informed decision making among a collaboration of healthcare practitioners. They developed patient similarity analytics that address the issue of how to identify patients that are clinically similar to an index patient, given longitudinal medical records of both the index patient and other patients in the population, i.e., patients belonging to the same PCMH. The insights drawn from the cohort of similar patients are used to provide support for diagnostic, treatment, and care management, particularly for complex patients with multiple comorbidities who do not fall neatly into categories defined in published clinical practice guidelines. One of the key challenges was the identification of the correct similarity metric to use in order for the results to have a clinical meaning. The team developed machine learning methodologies that are used to automatically adjust the similarity metric and the weighting among different features by leveraging domain knowledge. Client evaluations of the system highlight the fact that the display of cohorts helps to guide a better treatment process and improves quality of care.
The team at the IBM China Research Laboratory [98] [99] [100] extended the collaborative care model by first developing technologies that are directed toward patient engagement (called evidence-based patient-centered collaborative care), and then by developing technologies that instantiate both the EE and the BInternet of things[ vision to provide personalized health service (called Connected Health).
The IBM Taiwan Collaboratory team [101, 102] instantiated the evidence ecosystem in the form of their wellness cloud, which enables patients who are normally monitored by sensors to get personalized feedback on their progress in achieving their health goals. The approach has been proven to improve health outcomes and lower costs [103] .
Reducing essential hypertension
The team at the IBM Haifa Research Laboratory [104] utilized the evidence platform to help first in the construction of a genetic-epidemiological model for essential hypertension, and its related organ damage, which is known to affect 50% of the population older than 60 years of age, then in the improvement of diagnostic accuracy, and finally in the introduction of new strategies for early detection, prevention, and therapy selection. This work forms the foundation for more personalized treatment for such diseases.
Adverse drug event detection
The IBM Almaden Research team leveraged the EE to develop technology that mines adverse drug event (ADE) data to discover evidence of new ADEs and drug-to-drug interactions in large clinical databases. The effort addressed the challenges of utilizing temporal relationships between events, measuring and ranking the strength and the confidence of associations between drugs or drug combinations and diagnostic events, and limiting the bias caused by confounding factors such as preexisting medical conditions. Grounded in survival analysis, the team's method defines a statistical model for patient history records, which specifies one or more parameters for every association that is measured. The statistical data model extends the Cox method [32, 33] to simultaneously describe all significant influences of current and prior drug treatments, as well as of prior clinical events, on the hazards of subsequent clinical events at any point of time, as long as they make a specified frequency threshold in the population sample. This work has significantly mitigated the effects of overfitting and confounding factors, thus producing better predictions.
Preventing the spread of epidemics
The team at the IBM Almaden Research Center [105] [106] [107] utilized the evidence ecosystem to allow scientists to reuse data and disease (propagation) models, to rapidly build upon the work of others, and to accelerate the development and testing of new simulation software. In Figure 3 , the H1N1 incidence predicted by the base model (red) is shown along with the actual incidence data for Mexico City (blue). The team then introduced and tested an extended model against the base model. The extended model was designed to evaluate the possible effect of the social distancing policies put in place. In a blind experiment, an automated experiment was allowed to add a finite time window placed at any start date. It was shown that, within the window, the minimum error corresponded to a reduction in transmission of approximately 22%. The results demonstrated that school closure and other social distancing measures used in Mexico City can be effective in lowering influenza transmission in the midst of a pandemic.
Optimizing HIV therapy strategies The IBM Haifa Research Laboratory team [108] [109] [110] [111] has been working in a consortium with a number of European partners called EuResist on accumulating in vitro patients' data and creating a clinical decision support system that is based on the analysis of not only genome data but also clinical and demographic data. A number of mechanisms were used to create an accurate classifier, i.e., a specialized EU advanced analytic, which achieves quality recommendation results.
In order to validate the system's recommendations, a test was conducted where the team set aside treatment outcome and asked physicians and the automated server machine to estimate whether a given treatment is efficient or not [111] . Table 1 shows the results and highlights the fact that the system almost always outperforms experts and, thus, can be used to provide better care.
All of these instances of the evidence ecosystem provide good starting points in the transformational use of IT to improve the quality of care, reduce medical costs and errors, and decrease the complexity inherent in the medical field. However, there is a lot more work to be done in the future.
Future work
For EG, the next step is the facilitation of the ingest of more complex modalities such as audio and the use of advanced natural language processing techniques to better handle a wider range of free text documents and unstructured data from the Internet, for example, healthcare social networks. For EU, more advanced analytics need to be developed and deployed in order to create critical mass for the system such that there will be a pool of resources available that would allow easy customization to new environments. For incentive payment modeling, the models must be validated across a wide cross section of settings and feedback provided on the effect of localized evidence. On usability, the utilization of many novel omic (as in genomic) tests as outcome indicators has become part of the common practice for diagnosis, prognosis, and treatment [112] . These tests may include 1) the traditional procedure of sequencing a virus and identifying mutations in case of infection, 2) transcriptomic tests for breast cancer, and 3) characterizations of chromosomal aberrations in myeloma cells using comparative genomic hybridization. The interpretation of such omic tests requires expertise in epigenetic, evolution, or, more generally, bioinformatics; all are research areas that are not part of the knowledge of common physicians, and thus, decision support systems that integrate these tests will be critical in the future. Our ongoing work in this area involves creating data-driven tools and associated presentation technologies that learn from examples of similar patient cohorts and produce personalized recommendations that are based on the complex relation found between the genomic and clinical data.
The above set of future initiatives is not exhaustive and represents only the preliminary set of work items that the team will focus on.
Conclusion
IT holds the promise of enabling the transformation of the healthcare industry into an evidence-enhanced practice that enables better analytics and decision support for improved outcomes through the automated derivation of new and nonobvious insights from previously siloed repositories, improved treatment processes through the creation of personalized recommendations that incorporate targeted treatments based on individual characteristics, more complete wellness and outcome management through patient-centered and collaborative care, and improved payment systems that reward practitioners based on performance rather than service volume.
In this paper, we have presented IBM Research's vision of evidence-based healthcare and highlighted how the team of global researchers in China, Israel, Taiwan, and the United States is working to realize this vision, creating new classes of systems, techniques, and tools for care delivery. In the process, IBM Research has demonstrated how IBM's evidence-based ecosystem can be used to reduce transaction costs, improve quality of care, lower the number of medical errors and mistakes, and increase practitioner productivity. 
